PSN 375963 hydrochlorideGPR119 receptor agonist CAS# 388575-52-8 |
2D Structure
- MLN9708
Catalog No.:BCC2091
CAS No.:1201902-80-8
- MG-132
Catalog No.:BCC1227
CAS No.:133407-82-6
- Clasto-Lactacystin β-lactone
Catalog No.:BCC1224
CAS No.:154226-60-5
- Bortezomib (PS-341)
Catalog No.:BCC1238
CAS No.:179324-69-7
- CEP-18770
Catalog No.:BCC2093
CAS No.:847499-27-8
- AM 114
Catalog No.:BCC3589
CAS No.:856849-35-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 388575-52-8 | SDF | Download SDF |
PubChem ID | 56972228 | Appearance | Powder |
Formula | C17H24ClN3O | M.Wt | 321.84 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | 5-(4-butylcyclohexyl)-3-pyridin-4-yl-1,2,4-oxadiazole;hydrochloride | ||
SMILES | CCCCC1CCC(CC1)C2=NC(=NO2)C3=CC=NC=C3.Cl | ||
Standard InChIKey | ONDLSENXTCSHGC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H23N3O.ClH/c1-2-3-4-13-5-7-15(8-6-13)17-19-16(20-21-17)14-9-11-18-12-10-14;/h9-13,15H,2-8H2,1H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | GPR119 receptor agonist (EC50 values are 8.4 and 7.9 μM at human and mouse receptors respectively). Displays similar potency to the endogenous ligand oleylethanolamide (OEA). |
PSN 375963 hydrochloride Dilution Calculator
PSN 375963 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1071 mL | 15.5357 mL | 31.0713 mL | 62.1427 mL | 77.6783 mL |
5 mM | 0.6214 mL | 3.1071 mL | 6.2143 mL | 12.4285 mL | 15.5357 mL |
10 mM | 0.3107 mL | 1.5536 mL | 3.1071 mL | 6.2143 mL | 7.7678 mL |
50 mM | 0.0621 mL | 0.3107 mL | 0.6214 mL | 1.2429 mL | 1.5536 mL |
100 mM | 0.0311 mL | 0.1554 mL | 0.3107 mL | 0.6214 mL | 0.7768 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tetrahydroepiberberine
Catalog No.:BCN2649
CAS No.:38853-67-7
- Emodin-1-O-glucoside
Catalog No.:BCN8512
CAS No.:38840-23-2
- Lapatinib Ditosylate
Catalog No.:BCC2083
CAS No.:388082-78-8
- Tandutinib (MLN518)
Catalog No.:BCC4499
CAS No.:387867-13-2
- Tectoruside
Catalog No.:BCN8262
CAS No.:38784-73-5
- Muristerone A
Catalog No.:BCC2397
CAS No.:38778-30-2
- Tetrahydroisocucurbitacin I
Catalog No.:BCN7874
CAS No.:3877-89-2
- Cucurbitacin D
Catalog No.:BCN2355
CAS No.:3877-86-9
- Swazine
Catalog No.:BCN2143
CAS No.:38763-74-5
- Worenine
Catalog No.:BCN2557
CAS No.:38763-29-0
- Triptolide
Catalog No.:BCN5984
CAS No.:38748-32-2
- 3-Epibetulinic acid
Catalog No.:BCN8531
CAS No.:38736-77-5
- CK 869
Catalog No.:BCC6347
CAS No.:388592-44-7
- Z-Glu(OtBu)-OH
Catalog No.:BCC2776
CAS No.:3886-08-6
- Halaminol A
Catalog No.:BCN1788
CAS No.:389125-56-8
- Halaminol B
Catalog No.:BCN1748
CAS No.:389125-59-1
- Halaminol C
Catalog No.:BCN1787
CAS No.:389125-68-2
- erythro-Guaiacylglycerol
Catalog No.:BCN5440
CAS No.:38916-91-5
- Isodeoxyelephantopin
Catalog No.:BCN4638
CAS No.:38927-54-7
- SBHA
Catalog No.:BCC2425
CAS No.:38937-66-5
- Chelerythrine chloride
Catalog No.:BCN8322
CAS No.:3895-92-9
- Vitexin 4'-glucoside
Catalog No.:BCC9252
CAS No.:38950-94-6
- Isovitexin
Catalog No.:BCN5441
CAS No.:38953-85-4
- Icariside D2
Catalog No.:BCN7217
CAS No.:38954-02-8
Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells.[Pubmed:18724386]
Br J Pharmacol. 2008 Dec;155(7):1056-65.
BACKGROUND AND PURPOSE: GPR119 is a G protein-coupled receptor that is preferentially expressed in islet cells and mediates insulin secretion. Oleoyl-lysophosphatidylcholine and oleoylethanolamide (OEA) act as endogenous ligands for this receptor, whereas PSN375963 and PSN632408 are two recently reported synthetic agonists. In this study, we explored mechanisms underlying GPR119-induced insulin secretion. In addition, we assessed the potential utility of the synthetic agonists as tools for exploring GPR119 biology. EXPERIMENTAL APPROACH: We examined natural and synthetic GPR119 agonist activity at GPR119 in MIN6c4 and RINm5f insulinoma cells. We evaluated insulin secretion, intracellular calcium [Ca(2+)](i), ion channel involvement and levels of cAMP. KEY RESULTS: We report that increases in insulin secretion induced by OEA were associated with increased cAMP and a potentiation of glucose-stimulated increases in [Ca(2+)](i). We also demonstrate that ATP-sensitive K(+) and voltage-dependent calcium channels were required for GPR119-mediated increases in glucose-stimulated insulin secretion. In contrast to OEA, the synthetic GPR119 agonist PSN375963 and PSN632408 have divergent effects on insulin secretion, cAMP and intracellular calcium in MIN6c4 cells. CONCLUSIONS AND IMPLICATIONS: The endogenous ligand OEA signals through GPR119 in a manner similar to glucagon-like peptide-1 (GLP-1) and its receptor with respect to insulin secretion, [Ca(2+)](i) and cAMP. In addition, PSN375963 and PSN632408 substantially differ from OEA and from one another. These studies suggest that the commercially available synthetic agonists, although they do activate GPR119, may also activate GPR119-independent pathways and are thus unsuitable as GPR119-specific pharmacological tools.
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.[Pubmed:16517404]
Cell Metab. 2006 Mar;3(3):167-75.
The endogenous lipid signaling agent oleoylethanolamide (OEA) has recently been described as a peripherally acting agent that reduces food intake and body weight gain in rat feeding models. This paper presents evidence that OEA is an endogenous ligand of the orphan receptor GPR119, a G protein-coupled receptor (GPCR) expressed predominantly in the human and rodent pancreas and gastrointestinal tract and also in rodent brain, suggesting that the reported effects of OEA on food intake may be mediated, at least in part, via the GPR119 receptor. Furthermore, we have used the recombinant receptor to discover novel selective small-molecule GPR119 agonists, typified by PSN632408, which suppress food intake in rats and reduce body weight gain and white adipose tissue deposition upon subchronic oral administration to high-fat-fed rats. GPR119 therefore represents a novel and attractive potential target for the therapy of obesity and related metabolic disorders.